Piśmiennictwo

Medexpress

Opublikowano 16 pazdziernika 2022, 10:32

Medexpress

Opublikowano 16 pazdziernika 2022, 10:32

Piśmiennictwo:

  • Alizadehgharib S, Lehrkinder A, Alshabeeb A, Östberg AK, Lingström P. The effect of a nontobacco-based nicotine pouch on mucosal lesions caused by Swedish smokeless tobacco (snus). Eur J Oral Sci. 2022;130(4):e12885. doi:10.1111/eos.12885
  • Azzopardi D, Ebajemito J, McEwan M, et al. A randomised study to assess the nicotine pharmacokinetics of an oral nicotine pouch and two nicotine replacement therapy products. Sci Rep. 2022;12(1):6949. doi:10.1038/s41598-022-10544-x
  • Azzopardi D, Liu C, Murphy J. Chemical characterization of tobacco-free „modern” oral nicotine pouches and their position on the toxicant and risk continuums. Drug Chem Toxicol. 2021 May 25:1-9. doi: 10.1080/01480545.2021.1925691. Epub ahead of print. PMID: 34034614.
  • Berlowitz JB, Xie W, Harlow AF, Hamburg NM, Blaha MJ, Bhatnagar A, Benjamin EJ, Stokes AC. E-Cigarette Use and Risk of Cardiovascular Disease: A Longitudinal Analysis of the PATH Study (2013-2019). Circulation. 2022 May 17;145(20):1557-1559. doi: 10.1161/CIRCULATIONAHA.121.057369. Epub 2022 May 6. PMID: 35514292; PMCID: PMC9362726.
  • Bhatta DN, Glantz SA. Association of E-Cigarette Use With Respiratory Disease Among Adults: A Longitudinal Analysis. Am J Prev Med. 2020 Feb;58(2):182-190. doi: 10.1016/j.amepre.2019.07.028. Epub 2019 Dec 16. PMID: 31859175; PMCID: PMC6981012.
  • BinShabaib M, ALHarthi SS, Akram Z, Khan J, Rahman I, Romanos GE, Javed F. Clinical periodontal status and gingival crevicular fluid cytokine profile among cigarette-smokers, electronic-cigarette users and never-smokers. Arch Oral Biol. 2019 Jun;102:212-217. doi: 10.1016/j.archoralbio.2019.05.001. Epub 2019 May 3. PMID: 31078071.
  • Bishop E, East N, Bozhilova S, Santopietro S, Smart D, Taylor M, Meredith S, Baxter A, Breheny D, Thorne D, Gaca M. An approach for the extract generation and toxicological assessment of tobacco-free „modern’ oral nicotine pouches, Food Chem. Toxicol. 2020, 111713. Epub 2020 Sep 28. PMID: 32998027.
  • Campbell C, Feehan M, Kanitscheider C, Makena PS, Cai J, Baxter SA. Designing Studies to Inform Tobacco Harm Reduction: Learnings From an Oral Nicotine Pouch Actual Use Pilot Study. JMIR Form Res. 2022;6(8):e37573. doi:10.2196/37573.
  • Canistro D, Vivarelli F, Cirillo S, Babot Marquillas C, Buschini A, Lazzaretti M, Marchi L, Cardenia V, Rodriguez-Estrada MT, Lodovici M, Cipriani C, Lorenzini A, Croco E, Marchionni S, Franchi P, Lucarini M, Longo V, Della Croce CM, Vornoli A, Colacci A, Vaccari M, Sapone A, Paolini M. E-cigarettes induce toxicological effects that can raise the cancer risk. Sci Rep. 2017 May 17;7(1):2028. doi: 10.1038/s41598-017-02317-8. PMID: 28515485; PMCID: PMC5435699.
  • Chapman F, McDermott S, Rudd K, et al. A randomised, open-label, cross-over clinical study to evaluate the pharmacokinetic, pharmacodynamic and safety and tolerability profiles of tobaccofree oral nicotine pouches relative to cigarettes. Psychopharmacology (Berl). 2022;239(9):2931-2943. doi:10.1007/s00213-022-06178-6
  • Chidharla A, Agarwal K, Abdelwahed S, Bhandari R, Singh A, Rabbani R, Patel K, Singh P, Mehta D, Manaktala PS, Pillai S, Gupta S, Koritala T. Cancer Prevalence in E-Cigarette Users: A Retrospective Cross-Sectional NHANES Study. World J Oncol. 2022 Feb;13(1):20-26. doi: 10.14740/wjon1438. Epub 2022 Feb 8. PMID: 35317331; PMCID: PMC8913014.
  • Clarke E, Thompson K, Weaver S, Thompson J, O'Connell G. Snus: a compelling harm reduction alternative to cigarettes. Harm Reduct J. 2019 Nov 27;16(1):62. doi: 10.1186/s12954-019-0335-1. PMID: 31775744; PMCID: PMC6882181.
  • Committee on Toxicity of Chemicals in Food Consumer Products and the Environment (COT). Statement on the potential toxicological risks from electronic nicotine (and non-nicotine) delivery systems (E(N)NDS – e-cigarettes) www.cot.food.cov.uk: HM Government 2020.
  • Cunningham A, McAdam K, Thissen J, Digard H. The Evolving E-cigarette: Comparative Chemical Analyses of E-cigarette Vapor and Cigarette Smoke. Front Toxicol. 2020 Dec 15;2:586674. doi: 10.3389/ftox.2020.586674. PMID: 35296117; PMCID: PMC8915913.
  • East N, Bishop E, Breheny D, Gaca M, Thorne D. A screening approach for the evaluation of tobacco-free 'modern oral' nicotine products using Real Time Cell Analysis. Toxicol Rep. 2021 Feb 25;8:481-488. doi: 10.1016/j.toxrep.2021.02.014. PMID: 33718000; PMCID: PMC7933807.
  • Ebbert JO, Croghan IT, Schroeder DR, Hurt RD. A randomized phase II clinical trial of high-dosenicotine patch therapy for smokeless tobacco users. Nicotine Tob Res Off J Soc Res Nicotine Tob.2013;15(12):2037-2044. doi:10.1093/ntr/ntt097
  • Esteve F, Ballbè M, Sureda X, Fu M, Saltó E, Martínez-Sánchez JM. Particulate Matter from Electronic Cigarettes and Conventional Cigarettes: a Systematic Review and Observational Study. Curr Environ Health Rep. 2015 Dec;2(4):423-9. doi: 10.1007/s40572-015-0072-x. PMID: 26452675.
  • Fagerstrom K. A Comparison of Dependence across Different Types of Nicotine Containing Products and Coffee. Int J Environ Res Public Health. 2018 Jul 30;15(8):1609. doi: 10.3390/ijerph15081609. PMID: 30061507; PMCID: PMC6121467.
  • FDAa.https://www.fda.gov/tobacco-products/ctp-newsroom/fda-authorizes-reduced-exposure-claim-iqos-3-system-holder-and-charger.
  • FDAb. https://www.fda.gov/tobacco-products/advertising-and-promotion/fda-authorizes-modified-risk-tobacco-products
  • Flora JW, Meruva N, Huang CB, Wilkinson CT, Ballentine R, Smith DC, Werley MS, McKinney WJ. Characterization of potential impurities and degradation products in electronic cigarette formulations and aerosols. Regul Toxicol Pharmacol. 2016 Feb;74:1-11. doi: 10.1016/j.yrtph.2015.11.009. Epub 2015 Nov 30. PMID: 26617410.
  • Ganguly K, Nordström A, Thimraj TA, Rahman M, Ramström M, Sompa SI, Lin EZ, O'Brien F, Koelmel J, Ernstgård L, Johanson G, Pollitt KJG, Palmberg L, Upadhyay S. Addressing the challenges of E-cigarette safety profiling by assessment of pulmonary toxicological response in bronchial and alveolar mucosa models. Sci Rep. 2020 Nov 24;10(1):20460. doi: 10.1038/s41598-020-77452-w. PMID: 33235237; PMCID: PMC7686373.
  • Gathright EC, Wu WC, Scott-Sheldon LAJ. Electronic cigarette use among heart failure patients: Findings from the Population Assessment of Tobacco and Health study (Wave 1: 2013-2014). Heart Lung. 2020 May-Jun;49(3):229-232. doi: 10.1016/j.hrtlng.2019.11.006. Epub 2019 Dec 5. PMID: 31812280; PMCID: PMC7266714.
  • George J, Hussain M, Vadiveloo T, Ireland S, Hopkinson P, Struthers AD, Donnan PT, Khan F, Lang CC. Cardiovascular Effects of Switching From Tobacco Cigarettes to Electronic Cigarettes. J Am Coll Cardiol. 2019 Dec 24;74(25):3112-3120. doi: 10.1016/j.jacc.2019.09.067. Epub 2019 Nov 15. PMID: 31740017; PMCID: PMC6928567.
  • Gillman IG, Kistler KA, Stewart EW, Paolantonio AR. Effect of variable power levels on the yield of total aerosol mass and formation of aldehydes in e-cigarette aerosols. Regul Toxicol Pharmacol. 2016 Mar;75:58-65. doi: 10.1016/j.yrtph.2015.12.019. Epub 2015 Dec 29. PMID: 26743740.
  • GOLD. 2019. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2019 report. . Global Initiative for Chronic Obstructive Lung Disease.
  • Goniewicz ML, Knysak J, Gawron M, Kosmider L, Sobczak A, Kurek J, Prokopowicz A, Jablonska-Czapla M, Rosik-Dulewska C, Havel C, Jacob P 3rd, Benowitz N. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob Control. 2014 Mar;23(2):133-9. doi: 10.1136/tobaccocontrol-2012-050859. Epub 2013 Mar 6. PMID: 23467656; PMCID: PMC4154473.
  • Goniewicz ML, Smith DM, Edwards KC, Blount BC, Caldwell KL, Feng J, Wang L, Christensen C, Ambrose B, Borek N, van Bemmel D, Konkel K, Erives G, Stanton CA, Lambert E, Kimmel HL, Hatsukami D, Hecht SS, Niaura RS, Travers M, Lawrence C, Hyland AJ. Comparison of Nicotine and Toxicant Exposure in Users of Electronic Cigarettes and Combustible Cigarettes. JAMA Netw Open. 2018 Dec 7;1(8):e185937. doi: 10.1001/jamanetworkopen.2018.5937. PMID: 30646298; PMCID: PMC6324349.
  • Government of Canada: Vaping Product Regulations; 2018. Available at: https://www.canada.ca/en/health-canada/services/smoking-tobacco/vaping/product- safety-regulation.html (accessed August 9, 2022)
  • Greenhalgh E, Stillman, S., & Ford, C. . 7.1 Health and other benefits of quitting. 2020. In: Tobacco in Australia: Facts and issues [Internet]. Melbourne:
  • Cancer Council Victoria. Available from: http://www.tobaccoinaustralia.org.au/chapter-7-cessation/7-2-health-and-other-benefits-of-quitting.
  • Haswell LE, Baxter A, Banerjee A, Verrastro I, Mushonganono J, Adamson J, Thorne D, Gaça M, Minet E. Reduced biological effect of e-cigarette aerosol compared to cigarette smoke evaluated in vitro using normalized nicotine dose and RNA-seq-based toxicogenomics. Sci Rep. 2017 Apr 18;7(1):888. doi: 10.1038/s41598-017-00852-y. PMID: 28420881; PMCID: PMC5429854.
  • Health NCfCDPaHPUOoSa. Reports of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention (US); 2014.
  • Hurley S, Winnall, WR, Greenhalgh, EM & Winstanley, MH. . Tobacco in Australia: Facts and issues. [cited 2 November 2021]. Melbourne: Cancer Council Victoria; 2021.
  • Kantar. 2021. Attitudes of Europeans towards tobacco and electronic cigarettes. Special Eurobarometer 506. Brussels: European Commission.
  • Kondratieva, K. 2020. Russian Duma passes bill banning tobacco-free white pouches. Tobacco intelligence. Available from: https://tobaccointelligence.com/russia-gives-green-light-to-ban-tobacco-free-whitepouches/
  • Kosmider L, Sobczak A, Prokopowicz A, Kurek J, Zaciera M, Knysak J, Smith D, Goniewicz ML. Cherry-flavoured electronic cigarettes expose users to the inhalation irritant, benzaldehyde. Thorax. 2016 Apr;71(4):376-7. doi: 10.1136/thoraxjnl-2015-207895. Epub 2016 Jan 28. PMID: 26822067; PMCID: PMC4937616.
  • Lauterbach JH, Laugesen M. Comparison of Toxicant Levels in Mainstream Aerosols Generated byRuyan® Electronic Nicotine Delivery Systems (ENDS)and Conventional Cigarette Products; Poster #1861presented at the Society of Toxicology 51st AnnualMeeting & ToxExpo, San Francisco, CA, USA, March2012a
  • Lauterbach JH, M. Laugesen and Ross JD. Sug-gested Protocol for Estimation of Harmful and Poten-tially Harmful Constituents in Mainstream AerosolsGenerated by Electronic Nicotine Delivery Systems(ENDS); Poster #1860 presented at the Society ofToxicology 51st Annual Meeting & ToxExpo, SanFrancisco, CA, USA, March 2012.b
  • Lenton S., Single E.: The definition of harm reduction. Drug Alcohol Review, 1997, 17, 296-301
  • Lunell, E.; Fagerström, K.; Hughes, J.; Pendrill, R. Pharmacokinetic Comparison of a Novel Non-tobacco-Based Nicotine Pouch (ZYN) With Conventional, Tobacco-Based Swedish Snus and American Moist Snuff. Nicotine Tob Res. 2020, 22, 1757–1763.
  • Margham J, McAdam K, Forster M, Liu C, Wright C, Mariner D, Proctor C. Chemical Composition of Aerosol from an E-Cigarette: A Quantitative Comparison with Cigarette Smoke. Chem Res Toxicol. 2016 Oct 17;29(10):1662-1678. doi: 10.1021/acs.chemrestox.6b00188. Epub 2016 Sep 18. PMID: 27641760.
  • McNeill A, Brose LS,. Calder R, Bauld L, and Robson D: Evidence Review of E-Cigarettes and HeatedTobacco Products 2018. A Report Commissioned byPublic Health England;
  • McNeill A, Brose LS, Calder R, Simonavicius E & Robson D. Vaping in England: an evidence update including vaping for smoking cessation, February 2021 A report commissioned by Public Health England. London: Public Health England.
  • McNeill, A., L.S. Brose, R. Calder, L. Bauld, and D.Robson: Vaping in England: An Evidence Update. AReport Commissioned by Public Health England;2019. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/821179/Vaping_in_England_an_evidence_update_February_2019.pdf
  • McNeill, A, Simonavičius, E, Brose, LS, Taylor, E, East, K, Zuikova, E, Calder, R and Robson, D (2022). Nicotine vaping in England: an evidence update including health risks and perceptions, September 2022. A report commissioned by the Office for Health Improvement and Disparities. London: Office for Health Improvement and Disparities.
  • Miller-Holt J, Baskerville-Abraham I, Sakimura M, Fukushima T, Puglisi A, Gafner J. In vitro evaluation of mutagenic, cytotoxic, genotoxic and oral irritation potential of nicotine pouch products. Toxicol Rep. 2022;9:1316-1324. doi:10.1016/j.toxrep.2022.06.008
  • Miluna S, Melderis R, Briuka L, et al. The Correlation of Swedish Snus, Nicotine Pouches and Other Tobacco Products with Oral Mucosal Health and Salivary Biomarkers. Dent J. 2022;10(8):154. doi:10.3390/dj10080154
  • Murphy J, Gaca M, Lowe F, Minet E, Breheny D, Prasad K, Camacho O, Fearon IM, Liu C, Wright C, McAdam K, Proctor C. Assessing modified risk tobacco and nicotine products: Description of the scientific framework and assessment of a closed modular electronic cigarette. Regul Toxicol Pharmacol. 2017 Nov;90:342-357. doi: 10.1016/j.yrtph.2017.09.008. Epub 2017 Sep 25. PMID: 28954704.
  • National Academies of Sciences Engineering andMedicine; Health and Medicine Division; Board onPopulation Health and Public Health Practice;Committee on the Review of the Health Effects ofElectronic Nicotine Delivery Systems: Public HealthConsequences of E-Cigarettes; edited by D.L. Eaton,L.Y. Kwan and K. Stratton, National Academies Press,Washington, DC, USA, 2018. DOI: 10.17226/24952
  • New Zealand Ministry of Health: Vaping Facts; 2019. Available at: https://vapingfacts.health.nz (accessed August 13, 2022)
  • NFZ o zdrowiu. Choroby odtytoniowe. Raport 2021. Narodowy Fundusz Zdrowia; 2021.
  • Palmer AM, Toll BA, Carpenter MJ, et al. Reappraising Choice in Addiction: Novel Conceptualizations and Treatments for Tobacco Use Disorder. Nicotine Tob Res Off J Soc Res Nicotine Tob. 2022;24(1):3-9. doi:10.1093/ntr/ntab148
  • Perdyan A, Jassem J. Impact of Tobacco Smoking on Outcomes of Radiotherapy: A Narrative Review. Current oncology (Toronto, Ont). 2022;29(4):2284-300.
  • Peto R LA, Pan H, Boreham J, Thun M. 2015. Mortality from smoking in developed countries, 1950−2020. https://gas.ctsu.ox.ac.uk/tobacco/C4230.pdf.
  • Polosa R, Morjaria JB, Prosperini U, Busà B, Pennisi A, Malerba M, Maglia M, Caponnetto P. COPD smokers who switched to e-cigarettes: health outcomes at 5-year follow up. Ther Adv Chronic Dis. 2020 Oct 10;11:2040622320961617. doi: 10.1177/2040622320961617. PMID: 33101622; PMCID: PMC7549158.
  • Raport Beca Available from.2022. https://www.europarl.europa.eu/doceo/document/TA-9-2022-0038_EN.html
  • Rensch J, Liu J, Wang J, Vansickel A, Edmiston J, Sarkar M. Nicotine pharmacokinetics and subjective response among adult smokers using different flavors of on!® nicotine pouches compared to combustible cigarettes. Psychopharmacology (Berl). 2021;238(11):3325-3334. doi:10.1007/s00213-021-05948-y
  • Round EK, Chen P, Taylor AK, Schmidt E. Biomarkers of Tobacco Exposure Decrease After Smokers Switch to an E-Cigarette or Nicotine Gum. Nicotine Tob Res. 2019 Aug 19;21(9):1239-1247. doi: 10.1093/ntr/nty140. PMID: 30202883; PMCID: PMC6698949.
  • Shahab L, Goniewicz ML, Blount BC, Brown J, McNeill A, Alwis KU, Feng J, Wang L, West R. Nicotine, Carcinogen, and Toxin Exposure in Long-Term E-Cigarette and Nicotine Replacement Therapy Users: A Cross-sectional Study. Ann Intern Med. 2017 Mar 21;166(6):390-400. doi: 10.7326/M16-1107. Epub 2017 Feb 7. PMID: 28166548; PMCID: PMC5362067.
  • Song MA, Reisinger SA, Freudenheim JL, Brasky TM, Mathé EA, McElroy JP, Nickerson QA, Weng DY, Wewers MD, Shields PG. Effects of Electronic Cigarette Constituents on the Human Lung: A Pilot Clinical Trial. Cancer Prev Res (Phila). 2020 Feb;13(2):145-152. doi: 10.1158/1940-6207.CAPR-19-0400. Epub 2019 Oct 16. PMID: 31619441; PMCID: PMC7007320.
  • Song MA, Freudenheim JL, Brasky TM, Mathe EA, McElroy JP, Nickerson QA, Reisinger SA, Smiraglia DJ, Weng DY, Ying KL, Wewers MD, Shields PG. Biomarkers of Exposure and Effect in the Lungs of Smokers, Nonsmokers, and Electronic Cigarette Users. Cancer Epidemiol Biomarkers Prev. 2020 Feb;29(2):443-451. doi: 10.1158/1055-9965.EPI-19-1245. Epub 2019 Dec 17. PMID: 31848205; PMCID: PMC7064803.
  • Stratton K, Shetty P, Wallace R, Bondurant S. Clearing the smoke: the science base for tobacco harm reduction--executive summary. Tob Control. 2001 Jun;10(2):189-95. doi: 10.1136/tc.10.2.189. PMID: 11387543; PMCID: PMC1747561.
  • Tatarsky A., Redukcja szkód w psychoterapii. Nowe podejście w leczeniu uzależnień od narkotyków i alkoholu, Krajowe Biuro ds. Przeciwdziałania Narkomanii. Warszawa 2012
  • The European Commission. Special Eurobarometer 458. Attitudes of Europeans towards tobacco and electronic cigarettes. 2017. http://ec.europa.eu/commfrontoffice/publicopinion/index.cfm/Survey/getSurveyDetail/instruments/SPECIAL/surveyKy/2146. Accessed 20 Feb
  • Wagener TL, Floyd EL, Stepanov I, Driskill LM, Frank SG, Meier E, Leavens EL, Tackett AP, Molina N, Queimado L. Have combustible cigarettes met their match? The nicotine delivery profiles and harmful constituent exposures of second-generation and third-generation electronic cigarette users. Tob Control. 2017 Mar;26(e1):e23-e28. doi: 10.1136/tobaccocontrol-2016-053041. Epub 2016 Oct 11. PMID: 27729564; PMCID: PMC5574194.
  • Walele T, Bush J, Koch A, Savioz R, Martin C, O'Connell G. Evaluation of the safety profile of an electronic vapour product used for two years by smokers in a real-life setting. Regul Toxicol Pharmacol. 2018 Feb;92:226-238. doi: 10.1016/j.yrtph.2017.12.010. Epub 2017 Dec 14. PMID: 29248487
  • Watson M.: Harm reduction - Why do it?. International Journal of Drug Policy, 1991, 2, 13-15
  • WHO, 2017, Lexicon of alcohol and drug terms published by the World Health Organization, http://www.who.int/substance_abuse/terminology/who_lexicon/en/
  • WHO, 2001. Formaldehyde. Geneva: WHO. Available from: http://www.euro.who.int/__data/assets/pdf_file/0014/123062/AQG2ndEd_5_8Formaldehyde
  • WHO. European health report 2018: More than numbers – evidence for all. World Health Organisation, Regional Office for Europe.
  • Wytyczne leczenia uzależnienia od nikotyny, 2022, https://www.mp.pl/pulmonologia/artykuly-wytyczne/inne/299129,wytyczne-leczenia-uzaleznienia-od-nikotyny-2022
  • Ye D, Gajendra S, Lawyer G, Jadeja N, Pishey D, Pathagunti S, Lyons J, Veazie P, Watson G, McIntosh S, Rahman I. Inflammatory biomarkers and growth factors in saliva and gingival crevicular fluid of e-cigarette users, cigarette smokers, and dual smokers: A pilot study. J Periodontol. 2020 Oct;91(10):1274-1283. doi: 10.1002/JPER.19-0457. Epub 2020 Mar 16. PMID: 32052441; PMCID: PMC9014419.
  • Yu F, Rudd K, Pour SJ, et al. Preclinical Assessment of Tobacco-Free Nicotine Pouches Demonstrates Reduced In Vitro Toxicity Compared with Tobacco Snus and Combustible Cigarette Smoke. Appl Vitro Toxicol. 2022;8(1):24-35. doi:10.1089/aivt.2021.0020
  • Yuan JM, Carmella SG, Wang R, Tan YT, Adams-Haduch J, Gao YT, Hecht SS. Relationship of the oxidative damage biomarker 8-epi-prostaglandin F2α to risk of lung cancer development in the Shanghai Cohort Study. Carcinogenesis. 2018 Jul 3;39(7):948-954. doi: 10.1093/carcin/bgy060. PMID: 29726912; PMCID: PMC7190890.
  • Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004 Sep 11-17;364(9438):937-52. doi: 10.1016/S0140-6736(04)17018-9. PMID: 15364185.
Pobierz ten artykuł w formacie .pdf

Tematy

202211

podobne

PN WT ŚR CZ PT SO ND
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31